Qualigen Therapeutics, Inc. Files Amendment to S-1 Registration Statement

TL;DR

<b>Qualigen Therapeutics, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities.</b>

AI Summary

Qualigen Therapeutics, Inc. (AIXC) filed a Amended IPO Registration (S-1/A) with the SEC on May 6, 2024. Qualigen Therapeutics, Inc. filed an Amendment No. 2 to its Form S-1 Registration Statement. The filing is for the registration of securities under the Securities Act of 1933. The company is incorporated in Delaware and its fiscal year ends on December 31st. Qualigen Therapeutics, Inc. is classified as a smaller reporting company and a non-accelerated filer. The principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California.

Why It Matters

For investors and stakeholders tracking Qualigen Therapeutics, Inc., this filing contains several important signals. This S-1/A filing signifies that Qualigen Therapeutics is actively pursuing a public offering or has outstanding securities that require registration with the SEC. As a smaller reporting company and non-accelerated filer, Qualigen Therapeutics may have different disclosure requirements and market perceptions compared to larger, more established companies.

Risk Assessment

Risk Level: low — Qualigen Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies engaging in securities offerings and does not inherently indicate significant new risks.

Analyst Insight

Monitor future filings for details on the proposed securities offering, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 333-272623 — SEC File Number (Registration Statement)
• 20240506 — Filing Date (Amendment No. 2)
• 26-3474527 — IRS Employer Identification Number (Company Tax ID)

Key Players & Entities

• Qualigen Therapeutics, Inc. (company) — Registrant
• Securities Act of 1933 (regulator) — Act under which registration is filed
• Delaware (company) — State of incorporation
• Michael S. Poirier (person) — Chief Executive Officer
• Stradling Yocca Carlson & Rauth LLP (company) — Legal counsel
• Sullivan & Worcester LLP (company) — Legal counsel

FAQ

Industry Context

Qualigen Therapeutics, Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered and the proposed offering.
2. Track subsequent SEC filings from Qualigen Therapeutics for updates on the registration process and potential public offering.
3. Analyze the company's financial health and business strategy in conjunction with this registration statement.

Year-Over-Year Comparison

This is an amendment (Amendment No. 2) to a previously filed S-1 registration statement, indicating ongoing regulatory processes for securities registration.

Key Financial Figures

• $10,000,000 — ject to Completion Dated May 3, 2024. $10,000,000 Up to 33,333,333 Shares of (or Pre-Fu
• $10 million — sonable best efforts&rdquo; basis up to $10 million of shares of common stock, par value $0
• $0.001 — on of shares of common stock, par value $0.001 per share (the &ldquo;common stock&rdqu
• $0.30 — will have an initial exercise price of $0.30 per share and will have a five-year ter
• $800,000 — ed that we would invest an aggregate of $800,000 in Marizyme in April 2024 (the &ldquo;F
• $200,000 — ding Payment&rdquo;) and pay Marizyme a $200,000 Exclusivity Fee. (Provided, that if the
• $1,500,000 — d from time to time to up to a total of $1,500,000.) To date our Funding Payment investmen
• $500,000 — our Funding Payment investment has been $500,000. The Funding Payment is designed to pro
• $5.4 million — t purchase price for Qualigen, Inc. was $5.4 million in cash, of which $450,000 is being hel
• $450,000 — Inc. was $5.4 million in cash, of which $450,000 is being held in escrow to satisfy cert
• $560,000 — xcept for obligations to lend NanoSynex $560,000 on or before November 30, 2023, and $67
• $670,000 — 000 on or before November 30, 2023, and $670,000 on or before March 31, 2024), surrender
• $3.0 million — n, we agreed to surrender approximately $3.0 million of promissory notes which NanoSynex had
• $3.2 million — s waived, a potential savings of around $3.2 million (as of fiscal year 2023) for applicatio

Filing Documents

• forms-1a.htm (S-1/A) — 736KB
• ex23-1.htm (EX-23.1) — 4KB
• forms-1a_001.jpg (GRAPHIC) — 14KB
• 0001493152-24-017806.txt (&nbsp;) — 760KB

RISK FACTORS

RISK FACTORS 14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 20

USE OF PROCEEDS

USE OF PROCEEDS 21 DIVIDEND POLICY 22 CAPITALIZATION 22

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 25

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 29 PLAN OF DISTRIBUTION 32 LEGAL MATTERS 34 EXPERTS 34 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 34 WHERE YOU CAN FIND MORE INFORMATION 35 Neither we nor the placement agent has authorized anyone to provide any information or to make any representations other than those contained in or incorporated by reference in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the placement agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in or incorporated by reference in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our shares of common stock. Our business, financial condition, results of operations and prospects may have changed since that date. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the Securities and Exchange Commission, or the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated by reference having a later date, the statement in the document having the late date modifies or supersedes the earlier statement. No action is being taken in any jurisdiction outside the United States to permit a public offering of our shares of common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come in

View Full Filing

View this S-1/A filing on SEC EDGAR